Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Long-Term Investments (2024 - 2025)

Historic Long-Term Investments for Stoke Therapeutics (STOK) over the last 2 years, with Q3 2025 value amounting to $80.3 million.

  • Stoke Therapeutics' Long-Term Investments rose 16814.57% to $80.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $80.3 million, marking a year-over-year increase of 16814.57%. This contributed to the annual value of $29.8 million for FY2024, which is N/A changed from last year.
  • Stoke Therapeutics' Long-Term Investments amounted to $80.3 million in Q3 2025, which was up 16814.57% from $107.3 million recorded in Q2 2025.
  • Stoke Therapeutics' Long-Term Investments' 5-year high stood at $107.3 million during Q2 2025, with a 5-year trough of $23.0 million in Q1 2025.